EvolveImmune Therapeutics

EvolveImmune Therapeutics is developing therapeutics to block or upregulate immune system targets. Co-founders include Sidi Chen and Charlie Fuchs of Yale University and CEO Stephen Block. Elm Street Ventures invested in the Series A preferred stock financing alongside Pfizer Ventures, Takeda Ventures, and several other investors.